These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 23492884

  • 1. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
    Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, Weber WA, Mansi R.
    J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
    [Abstract] [Full Text] [Related]

  • 2. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee Sy, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [Abstract] [Full Text] [Related]

  • 3. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee SY, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [Abstract] [Full Text] [Related]

  • 4. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 5. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
    Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, Vorobyeva A, Larhed M, Tolmachev V, de Jong M, Rosenström U, Orlova A.
    Int J Cancer; 2019 Dec 15; 145(12):3347-3358. PubMed ID: 31077356
    [Abstract] [Full Text] [Related]

  • 6. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE.
    J Nucl Med; 2009 Dec 15; 50(12):2017-24. PubMed ID: 19910427
    [Abstract] [Full Text] [Related]

  • 7. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
    Stott Reynolds TJ, Schehr R, Liu D, Xu J, Miao Y, Hoffman TJ, Rold TL, Lewis MR, Smith CJ.
    Nucl Med Biol; 2015 Feb 15; 42(2):99-108. PubMed ID: 25459113
    [Abstract] [Full Text] [Related]

  • 8. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
    Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu L, Miao Y, Reynolds TS, Smith CJ.
    Nucl Med Biol; 2014 Feb 15; 41(2):133-9. PubMed ID: 24480266
    [Abstract] [Full Text] [Related]

  • 9. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA.
    J Nucl Med; 2017 Jan 15; 58(1):29-35. PubMed ID: 27516447
    [Abstract] [Full Text] [Related]

  • 10. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD.
    J Nucl Med; 2006 Jul 15; 47(7):1144-52. PubMed ID: 16818949
    [Abstract] [Full Text] [Related]

  • 11. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.
    Damiana TST, Paraïso P, de Ridder C, Stuurman D, Seimbille Y, Dalm SU.
    Eur J Nucl Med Mol Imaging; 2023 Nov 15; 50(13):3851-3861. PubMed ID: 37584725
    [Abstract] [Full Text] [Related]

  • 12. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, Barbato D, Tedesco M, Maina T, Nock BA, de Jong M.
    J Nucl Med; 2017 Feb 15; 58(2):293-299. PubMed ID: 27609789
    [Abstract] [Full Text] [Related]

  • 13. Substitution of l-Tryptophan by α-Methyl-l-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability.
    Günther T, Deiser S, Felber V, Beck R, Wester HJ.
    J Nucl Med; 2022 Sep 15; 63(9):1364-1370. PubMed ID: 35027371
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT.
    Wieser G, Popp I, Christian Rischke H, Drendel V, Grosu AL, Bartholomä M, Weber WA, Mansi R, Wetterauer U, Schultze-Seemann W, Meyer PT, Jilg CA.
    Eur J Nucl Med Mol Imaging; 2017 Aug 15; 44(9):1463-1472. PubMed ID: 28417160
    [Abstract] [Full Text] [Related]

  • 15. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.
    Kurth J, Krause BJ, Schwarzenböck SM, Bergner C, Hakenberg OW, Heuschkel M.
    Eur J Nucl Med Mol Imaging; 2020 Jan 15; 47(1):123-135. PubMed ID: 31482426
    [Abstract] [Full Text] [Related]

  • 16. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
    Jiang L, Miao Z, Liu H, Ren G, Bao A, Cutler CS, Shi H, Cheng Z.
    Nucl Med Commun; 2013 Sep 15; 34(9):909-14. PubMed ID: 23708872
    [Abstract] [Full Text] [Related]

  • 17. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D, Balkin ER, Jia F, Ruthengael VC, Smith CJ, Lewis MR.
    Nucl Med Biol; 2015 Sep 15; 42(9):704-10. PubMed ID: 26081917
    [Abstract] [Full Text] [Related]

  • 18. Single vial cold kits optimized for preparation of gastrin releasing peptide receptor (GRPR)-radioantagonist 68Ga-RM2 using three different 68Ge/68Ga generators.
    Vats K, Sharma R, Kameswaran M, Satpati D, Dash A.
    J Pharm Biomed Anal; 2019 Jan 30; 163():39-44. PubMed ID: 30278325
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
    Johnson CV, Shelton T, Smith CJ, Ma L, Perry MC, Volkert WA, Hoffman TJ.
    Cancer Biother Radiopharm; 2006 Apr 30; 21(2):155-66. PubMed ID: 16706636
    [Abstract] [Full Text] [Related]

  • 20. In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.
    Chatalic KL, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, Brunel L, Fehrentz JA, Martinez J, van Gent DC, Nock BA, Maina T, van Weerden WM, de Jong M.
    Theranostics; 2016 Apr 30; 6(1):104-17. PubMed ID: 26722377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.